/ Print /

Policy & Regulation Strategy

Four healthcare policy changes to watch in 2018Insiders unmask what policy actions will continue and what will develop in the next year.
Is there a simple fix for the Part D discount program?A poll from the Biosimilars Council, a division of the Association for Accessible Medicines, has interesting findings about placing biosimilars and branded biologics on a level playing field to save money.
Top 2018 challenges healthcare executives faceExperts weigh in on the findings from Managed Healtcare Executive’s 2017 State of the Industry Survey.
Three things to know about Trump’s HHS lead pick AzarExperts share more about Alex Azar’s background and predict what his top agenda items are likely to be.
Controversy heats up over pharmacy benefit manager DIR feesPBMs make the argument for DIR fees after a litany of complaints from industry stakeholders.
Six healthcare interoperability barriers to watch
Six healthcare interoperability barriers to watchIs interoperability in healthcare a dream, or will payers, providers, and technology vendors finally come together to make data more available to one another?
Opinion: Trump’s executive order will have limited impact on insurance marketWhile many analyses of Section 1a of the executive order cite doom and gloom for health plans, four tenuous contingencies all must take place in order for this to occur.
Payers struggle to keep up with high rate of FDA drug approvalsFDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.
Survey: How payers use nonpayer generated data to make formulary decisionsExternal, non-payer generated data can inform formulary decision-making—if payers know their strengths and weaknesses.
Specialty drug pipeline predictions: Seven key areas to watchThe specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.